Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intraven...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine Vol. 194; p. 106776
Main Authors: Bendien, S.A., van Leeuwen, M.M., Lau, H.S., Ten Brinke, A., Visser, L.E., de Koning, E.M., Braunstahl, G.J.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-04-2022
Subjects:
Anti-Asthmatic Agents - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma - drug therapy
Biologics
Home administration
Humans
Netherlands - epidemiology
Severe asthma
Netherlands
ATS
IL
IM
ERS
AQLQ
Home administration
IV
SEA
SA
ACQ
SC
Biologics
HA
Severe asthma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital. •The worldwide COVID-19 pandemic urges us to speed up implementation of home treatment for chronic diseases such as severe asthma.•Intravenous reslizumab can be administered safely and successfully in an outpatient setting.•Patients with severe asthma have different needs when it comes to choosing in-hospital or home treatment with biologics.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2022.106776